Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jun;35(6):1247–1249. doi: 10.1128/aac.35.6.1247

Pharmacokinetics of 2',3'-dideoxyinosine in monkeys.

M X Qian 1, T S Finco 1, A R Swagler 1, J M Gallo 1
PMCID: PMC284324  PMID: 1929275

Abstract

Comparison of the pharmacokinetic parameters obtained for dideoxyinosine (ddI) in monkeys with those obtained for humans indicates that the monkey is an appropriate animal model for ddI pharmacokinetics in humans. Following intravenous administration of 20 mg of ddI per kg of body weight and measurement of ddI in plasma and urine by high-performance liquid chromatography, pharmacokinetic parameters were determined by noncompartmental analysis. Total systemic clearance was 0.74 liters/h/kg, volume of distribution was 0.92 liters/kg, and the elimination half-life of ddI was 1.22 h. The pharmacokinetics of ddI in five monkeys were determined following intravenous administration of 20 mg/kg and were found to be comparable to those obtained in patients with AIDS.

Full text

PDF
1247

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson B. D., Hoesterey B. L., Baker D. C., Galinsky R. E. Uptake kinetics of 2',3'-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J Pharmacol Exp Ther. 1990 Apr;253(1):113–118. [PubMed] [Google Scholar]
  2. Chen M. S., Oshana S. C. Inhibition of HIV reverse transcriptase by 2',3'-dideoxynucleoside triphosphates. Biochem Pharmacol. 1987 Dec 15;36(24):4361–4362. doi: 10.1016/0006-2952(87)90685-x. [DOI] [PubMed] [Google Scholar]
  3. Cooley T. P., Kunches L. M., Saunders C. A., Perkins C. J., Kelley S. L., McLaren C., McCaffrey R. P., Liebman H. A. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S552–S560. doi: 10.1093/clinids/12.supplement_5.s552. [DOI] [PubMed] [Google Scholar]
  4. Dolin R., Lambert J. S., Morse G. D., Reichman R. C., Plank C. S., Reid J., Knupp C., McLaren C., Pettinelli C. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S540–S551. [PubMed] [Google Scholar]
  5. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  6. Mitsuya H., Broder S. Strategies for antiviral therapy in AIDS. 1987 Feb 26-Mar 4Nature. 325(6107):773–778. doi: 10.1038/325773a0. [DOI] [PubMed] [Google Scholar]
  7. Ray G. F., Mason W. D., Badr M. Z. Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat. Drug Metab Dispos. 1990 Sep-Oct;18(5):654–658. [PubMed] [Google Scholar]
  8. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  9. Russell J. W., Klunk L. J. Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Biochem Pharmacol. 1989 May 1;38(9):1385–1388. doi: 10.1016/0006-2952(89)90176-7. [DOI] [PubMed] [Google Scholar]
  10. Valentine F. T., Seidlin M., Hochster H., Laverty M. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S534–S539. doi: 10.1093/clinids/12.supplement_5.s534. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES